Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARBOARD: encorafenib + binimetinib + pembrolizumab vs placebo + pembrolizumab in BRAF V600E/K melanoma
2024-512038-13-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing encorafenib + binimetinib + pembrolizumab with placebo + pembrolizumab (2 arms). Primary endpoints: Safety lead-in: incidence of dose-limiting toxicities and Randomized Phase 3: objective response rate. Planned start Sep 2021; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-512038-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512038-13-00.